Aytu BioPharma, Inc. (AYTU)
AYTU Stock Price Chart
Explore Aytu BioPharma, Inc. interactive price chart. Choose custom timeframes to analyze AYTU price movements and trends.
AYTU Company Profile
Discover essential business fundamentals and corporate details for Aytu BioPharma, Inc. (AYTU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Sept 2008
Employees
102.00
Website
https://aytubio.comCEO
Joshua R. Disbrow
Description
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
AYTU Financial Timeline
Browse a chronological timeline of Aytu BioPharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Sept 2026
EPS estimate is -$0.29, while revenue estimate is $12.28m.
Upcoming earnings on 22 Sept 2026
EPS estimate is -$0.22, while revenue estimate is $17.18m.
Earnings released on 13 May 2026
EPS came in at -$0.53 falling short of the estimated -$0.31 by -70.97%, while revenue for the quarter reached $12.41m , beating expectations by +2.97%.
Earnings released on 3 Feb 2026
EPS came in at -$1.05 falling short of the estimated -$0.26 by -303.85%, while revenue for the quarter reached $15.20m , beating expectations by +24.85%.
Earnings released on 13 Nov 2025
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $13.89m , beating expectations by +10.24%.
Earnings released on 23 Sept 2025
EPS came in at -$0.26 falling short of the estimated -$0.02 by -1.20k%, while revenue for the quarter reached $15.14m , missing expectations by -15.55%.
Earnings released on 14 May 2025
EPS came in at $0.20 surpassing the estimated -$0.17 by +217.65%, while revenue for the quarter reached $18.45m , missing expectations by -2.02%.
Earnings released on 12 Feb 2025
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $16.22m , missing expectations by -7.77%.
Earnings released on 13 Nov 2024
EPS came in at -$0.20 surpassing the estimated -$0.34 by +41.18%, while revenue for the quarter reached $16.57m , beating expectations by +20.36%.
Earnings released on 26 Sept 2024
EPS came in at -$0.82 falling short of the estimated -$0.45 by -82.22%, while revenue for the quarter reached $17.98m , missing expectations by -1.77%.
Earnings released on 15 May 2024
EPS came in at -$0.52 surpassing the estimated -$0.64 by +18.75%, while revenue for the quarter reached $17.99m , missing expectations by -1.68%.
Earnings released on 14 Feb 2024
EPS came in at -$0.04 surpassing the estimated -$0.25 by +84.00%, while revenue for the quarter reached $22.93m , beating expectations by +5.49%.
Earnings released on 14 Nov 2023
EPS came in at -$1.48 falling short of the estimated -$0.04 by -3.60k%, while revenue for the quarter reached $22.10m , missing expectations by -20.31%.
Earnings released on 27 Sept 2023
EPS came in at $0.16 surpassing the estimated -$0.95 by +116.84%, while revenue for the quarter reached $30.73m , beating expectations by +10.99%.
Earnings released on 11 May 2023
EPS came in at -$1.93 falling short of the estimated -$0.63 by -206.35%, while revenue for the quarter reached $22.73m , missing expectations by -12.90%.
Earnings released on 21 Feb 2023
EPS came in at -$1.31 falling short of the estimated $0.20 by -755.00%, while revenue for the quarter reached $26.28m , missing expectations by -10.92%.
Stock split effective on 6 Jan 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$1.20 surpassing the estimated -$3.60 by +66.67%, while revenue for the quarter reached $27.66m , beating expectations by +13.81%.
Earnings released on 27 Sept 2022
EPS came in at -$5.00 falling short of the estimated -$4.80 by -4.17%, while revenue for the quarter reached $27.45m , beating expectations by +6.80%.
Earnings released on 16 May 2022
EPS came in at -$5.40 surpassing the estimated -$8.20 by +34.15%, while revenue for the quarter reached $24.20m , missing expectations by 0.00%.
Earnings released on 14 Feb 2022
EPS came in at -$8.80 falling short of the estimated -$7.09 by -24.14%, while revenue for the quarter reached $23.13m , beating expectations by +0.11%.
Earnings released on 15 Nov 2021
EPS came in at -$6.60 falling short of the estimated -$2.97 by -122.45%, while revenue for the quarter reached $21.90m , beating expectations by +19.99%.
Earnings released on 27 Sept 2021
EPS came in at -$13.40 falling short of the estimated -$3.20 by -318.75%, while revenue for the quarter reached $23.48m .
AYTU Stock Performance
Access detailed AYTU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
